PaoloCaimiMD

PubMed

• Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models.
  Jan Joseph Melenhorst, Paolo F Caimi> ;Cancer Immunology Research. 2024 Apr 2
• A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.
  Leland L Metheny, Ronald Sobecks, Christina Cho, Pingfu Fu, Seunghee Margevicius, Jiasheng Wang, Lisa Ciarrone, Shelby Kopp, Robin D Convents, Navneet Majhail, Paolo F...> ;Blood Advances. 2024 Mar 26
• BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cel...
  Robert Stuver, Agrima Mian, Samantha Brown, Sean Devlin, Paolo F Caimi, Stephanie Chinapen, Parastoo Dahi, Robert Dean, Zachary D Epstein-Peterson, Brian Hill, Steven ...> ;American Journal of Hematology. 2024 Mar 25
• Lenalidomide, rituximab (R), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.
  Chen, Y., Cooper, B., Hill, B., Jagadeesh, D., Dean, R., Koc, O., Boughan, K., Pohlman, B., Caimi, P., Smith, M.> ;Leukemia & Lymphoma. 2024 Mar 8
• In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine.
  Hamadani, M., Carlo-Stella, C., Nickaeen, M., Jordie, E., Utsey, K., Knab, T., Zammarchi, F., Cucchi, D., Pantano, S., Havenith, K., Wang, Y., Boni, J., Caimi, P.> ;Ejhaem. 2024 Feb 1
• 1 citations
  Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy.
  Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria R ...> ;Blood. 2024 Jan 22
• 1 citations
  Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial.
  Hamadani, M., Spira, A., Zhou, X., Liao, L., Chen, L., Radford, J., Ai, W., Solh, M., Ardeshna, K., Hess, B., Caimi, P., Stathis, A., Carlo-Stella, C., Alderuccio, J.,...> ;Blood Advances. 2024 Jan 9
• PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
  Alderuccio, J., Reis, I., Hamadani, M., Nachiappan, M., Leslom, S., Kahl, B., Ai, W., Radford, J., Solh, M., Ardeshna, K., Hess, B., Lunning, M., Zinzani, P., Stathis,...> ;Clinical Cancer Research. 2024 Jan 5
• 7 citations
  Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
  David A Qualls, Nicholas Lambert, Paolo F Caimi, Mwanasha Merrill, Priyanka Pullarkat, Richard C Godby, David A Bond, Graham T Wehmeyer, Jason Romancik, Behzad Amoozga...> ;Blood. 2023 Dec 28
• Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
  Gerson, J., Handorf, E., Villa, D., Gerrie, A., Chapani, P., Li, S., Medeiros, L., Wang, M., Cohen, J., Churnetski, M., Hill, B., Sawalha, Y., Hernandez-Ilizaliturri, ...> ;Blood Advances. 2023 Dec 26
• 3 citations
  NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
  Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, Ranjana H Advani, Babis Andreadis, Nancy L Bartlett, L Elizabeth Budde, Paolo F Caimi, Julie E Chang, Beth Christia...> ;Journal of the National Comprehensive Cancer Network. 2023 Nov 1
• A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma.
  Taylor R Brooks, Paolo F Caimi> ;Blood Reviews. 2024 Jan 1
• Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
  Barr, P. M., Barr, P. M., Barr, P. M., Karmali, R., Alexandra Rezazadeh, Aniko Szabo, Arushi Khurana, David J Inwards, Matthew A Lunning, Nancy L Bartlett, Paolo F Cai...> ;Haematologica. 2023 Oct 19
• The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma.
  Gabriel F P Aleixo, Wei Wei, Po-Hao Chen, Namita S Gandhi, Faiz Anwer, Robert Dean, Betty K Hamilton, Brian T Hill, Deepa Jagadeesh, Jack Khouri, Brad Pohlman, Ronald ...> ;Bone Marrow Transplantation. 2023 Dec 1
• 4 citations
  Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
  Paolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, Kirit M Ardeshna, Mehdi Hamadani, Brian Hess, Brad S Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi...> ;Haematologica. 2024 Apr 1
• Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells.
  Ke Zeng, Meixian Huang, Mi-Ae Lyu, Sairah Ahmed, Krina K Patel, Boro Dropulić, Jane Reese-Koc, Paolo F Caimi, Tara Sadeghi, Marcos de Lima, Christopher R Flowers, Simr...> ;Cells. 2023 Jul 18
• A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies.
  Rahul Mishra, Danai Dima, Sumukh A Kumar, Agrima Mian, Alankrita Taneja, Rahul Karna, Paolo F Caimi, Brian T Hill, Robert Dean, Deepa Jagadeesh> ;Hematological Oncology. 2023 Dec 1
• 3 citations
  Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
  Andrew L Coveler, David C Smith, Tycel Phillips, Brendan D Curti, Sanjay Goel, Amitkumar N Mehta, Timothy M Kuzel, Svetomir N Markovic, Olivier Rixe, David L Bajor, Th...> ;Journal for Immunotherapy of Cancer. 2023 Jun 1
• Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis.
  Akiva Diamond, Long Vu, Wyatt P Bensken, Siran M Koroukian, Paolo F Caimi> ;Leukemia. 2023 Jul 1
• 2 citations
  T-Cell Engagers in Solid Cancers-Current Landscape and Future Directions.
  Mohamed Shanshal, Paolo F Caimi, Alex A Adjei, Wen Wee Ma> ;Cancers. 2023 May 18
• 1 citations
  Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A ph...
  Julie M Vose, Siddhartha Ganguly, Philip J Bierman, R Gregory Bociek, Matthew Lunning, Liz Lyden, Jane L Meza, Paolo F Caimi, James O Armitage> ;British Journal of Haematology. 2023 Jul 1
• 3 citations
  Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients.
  Akiva Diamond, Wyatt P Bensken, Long Vu, Weichuan Dong, Siran M Koroukian, Paolo Caimi> ;JACC. Cardiooncology. 2023 Apr 1
• 1 citations
  Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel.
  Agrima Mian, Wei Wei, Betty K Hamilton, Allison M Winter, Jack Khouri, Brad Pohlman, Aaron T Gerds, Deepa Jagadeesh, Faiz Anwer, Matt Kalaycio, Robert M Dean, Ronald S...> ;Bone Marrow Transplantation. 2023 May 1
• 2 citations
  Postibrutinib relapse outcomes for patients with marginal zone lymphoma.
  Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K Moyo, Nishitha Reddy, Julia Sheets, David M Weiner, Praveen Ramakrishnan Geethakumar...> ;Blood Advances. 2023 Jan 10
• Editorial: Rising stars in hematology: 2022.
  Gavriilaki, E., de Lima, M., Caimi, P., Arat, M.> ;Frontiers in Medicine. 2023 Jan 1
• Join now to see all

Abstracts/Posters

• Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay
  Paolo F Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
  Paolo Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia
  Paolo Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
  Paolo F Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Tr...
  Paolo F Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
  Paolo Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF-_ S...
  Paolo Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
  Paolo Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)
  Paolo Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction
  Paolo F Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Phase 1 trial of anti-CD19 chimeric antigen receptor T (CAR-T) cells with tumor necrosis alfa receptor superfamily 19 (TNFRSF19) transmembrane domain. 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
• Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Maintenance Therapy on Nature of First Relapse in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplant 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Ref... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Direction of KIR Ligand Incompatibility Is Associated with Graft Failure and May Predict the Dominant Donor Following Double Umbilical Cord Blood Transplantation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Comparison of Pegfilgrastim and Filgrastim to Prevent Neutropenic Fever during Consolidation with High Dose Cytarabine for Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all